John has almost 20 years of experience in both large and small BioPharma progressing a number of projects through preclinical research to candidate drug nomination. Following a DPhil in Clinical Biochemistry at Oxford John went on to complete a Postdoctoral position in Peter Parker’s lab at the Institute for Cancer Research working on identifying and characterising a new class of kinases involved in cancer. John then worked for a small biotech company working in oncology and dermatology therapy areas and from here moved to Pfizer for 7 years where he worked on a number of drug discovery projects in Cardiovascular and Tissue Repair research areas. Subsequently he moved to AstraZeneca where he worked for 11 years at a senior leadership level in target identification and translational research supporting Oncology, Respiratory and Inflammation, and Cardiovascular research areas.
Andrew KayChairman of the Board
Mr. Andrew Kay brings more than 30 years of commercial and leadership experience in the pharmaceutical sector, latest as CEO of Algeta ASA. During Mr. Kay’s leadership, Algeta’s lead product, Xofigo, was approved by the FDA and EMA for the treatment of bone metastases in castration resistant prostate cancer patients, followed by a strong commercial launch. In February 2014, Algeta was acquired by its partner Bayer AG for USD 2.9 billion. Mr. Kay’s previous assignments include Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and several other senior commercial positions in Europe and the USA with AstraZeneca, Eli Lilly, Sandoz and Boots.
Rita DobmeyerBoard Member
Dr. Rita Dobmeyer is a graduate of the University of Kaiserslautern, Germany with degrees in Biology. She got a PHD at the German Cancer research Center, Heidelberg in infectiology and worked with the Nobel Prize award winner Luc Montagnier. Prior to founding GALENUS GmbH she was Director European Consulting and Client Relations for Parexel GmbH in Berlin Germany. Previous to Parexel, Dr. Dobmeyer was Director of Phase IV Clinical Services and Postmarketing Surveillance at IMS Health, a founding member of IBAH (CRO) and has extensive clinical trial experience in diverse companies. Rita was founder of 8 companies and is networked with investors and key opinion leaders around the world.
Dr. Rita Dobmeyer is an accomplished researcher and the author/co-author of more than 50 articles and several book chapters, has been a speaker for several international conferences, has consulted for several university-based drug development companies and is a board member of several foundations and companies.
Adrian HowdBoard Member
Adrian has extensive commercial, financial and biotech leadership experience, and leads Blueberry’s audit committee. He has considerable asset acquisition and strategic investment experience and has held various senior roles at Malin Corporation, Wren Therapeutics, Immunocore, Viamet, Evotec, Berenberg, Gossler & Co, ABN AMRO.
Dr Huaizheng PengBoard Member
Huaizheng has extensive pharmaceutical, commercial, investment banking and medical practice experience. In addition, Huaizheng has considerable asset acquisition, in/out licencing, and strategic investment experience. He is the director of CMS, Bridging, Top Ridge Pharma, and NCP Investment Management.
Bob ClayAdvisor to the board
Bob Clay is a pharmacist with more than 30 years’ experience in drug development, leading the global regulatory approval of many products across a range of therapy areas, including more than 15 new active substances. Previously, he was VP of Global Regulatory Affairs at AstraZeneca with responsibility for oncology, infection and personalised healthcare. Bob is a Fellow and board member at TOPRA (President in 2017) and a member of the Expert Scientific Advisory Committee for Medicines for Malaria Venture. Bob has held significant leadership roles in regulatory affairs in regional and global functions at Pfizer, AstraZeneca and Kinapse.
Friedrich K. MayerAdvisor to the board
Friedrich K. Mayer has 47 year’s experience in the pharmaceutical industry, both in drugs (small molecules and proteins) and vaccines. Starting in the Sandoz Research Institute in Vienna he moved to corporate headquarters in Basel, Switzerland (now Novartis) as Global Project Leader. He built and led multidisciplinary global project teams taking six NMEs from research through registration to life cycle management. These include Terbinafine (Lamisil®), the gold standard for the treatment of Onychomycosis, and the first allylamine antifungal, naftifine (Exoderil®/Naftin®). After retiring from Novartis he worked in small biotechnology firms. Friedrich has extensive experience in the areas of dermatology, infectious diseases (fungal, bacterial, viral and protozoal), gynecology, bone diseases, endocrinology, immunology, wound healing, veterinary medicine and medical devices.
Friedrich holds a Dr.Sc. (chemistry) from the University of Technology in Vienna, Austria and an MBA from INSEAD in Fontainebleau, France.
Vijay is an Investment Director with Catapult’s GM&C Life Sciences Fund. He has 12 years’ experience working in private equity. Vijay started his career at Schroders before working for Citigroup in London and New York. He then joined GlaxoSmithKline as a strategy consultant before moving to the corporate finance team at Deloitte, where he was an Assistant Director. After a stint with EmiratesNBD in Dubai, he then moved to Muscat to work for the Oman Investment Authority, the sovereign wealth fund of Oman. Thereafter, he was a Vice-President at the Investment Corporation of Dubai, a UAE sovereign wealth fund, where he was part of the team that managed over $10bn of assets. Most recently, he was based in Mauritius and led a $400m private equity fund focused on healthcare investments across sub-Saharan Africa.